Therapies potentially available in the Pediatric MATCH trial, and the mutations they target

• larotrectinib- targeting NTRK

• erdafitinib- targeting FGFR

• tazemetostat- targeting EZH2 and other SWI/SNF complex genes

• LY3023414- targeting the PI3K/MTOR pathway

• selumetinib- targeting the MAPK pathway

• ensartinib- targeting ALK or ROS1

• vemurafenib- targeting BRAF

• olaparib- targeting defects in DNA damage repair

• palbociclib- targeting cell cycle genes

• ulixertinib- targeting the MAPK pathway